LUNG: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-43,578	-29,621
Stock-based compensation expense	16,992	11,826
Impairment of capitalized software development costs	0	0
Change in allowance for credit losses	0	0
Inventory write-down (recovery), net	-24	-96
Depreciation and amortization expense	823	577
Amortization of debt discount and debt issuance costs	38	24
Net accretion of discounts on marketable securities	379	339
Non-cash lease expense	1,080	615
Accounts receivable	531	1,941
Inventory	-45	-1,066
Prepaid expenses and other current assets	-186	-1,099
Other assets	237	359
Accounts payable	2,766	2,645
Accrued liabilities	-1,836	-2,364
Income taxes payable	85	92
Lease liabilities	-674	-293
Deferred revenue	-48	-61
Net cash used in operating activities	-25,292	-17,130
Purchases of investments	5,651	5,651
Maturities of investments	36,585	27,785
Purchases of property and equipment and internal software development costs	439	350
Net cash provided by investing activities	30,495	21,784
Repayment of credit agreement	49	48
Debt issuance cost	70	47
Proceeds from exercise of common stock options	143	138
Proceeds from issuance of common stock under the employee stock purchase plan	754	554
Net cash provided by financing activities	778	597
Effect of exchange rate changes on cash and cash equivalents	-333	-688
Net increase (decrease) in cash, cash equivalents, and restricted cash	5,648	4,563
Cash and cash equivalents at beginning of period	71,162	-
Cash and cash equivalents at end of period	76,810	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

LUNG: the cashflow